GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
CA2473572C
(en)
|
2002-02-01 |
2011-05-10 |
Astrazeneca Ab |
Quinazoline compounds
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
JP4694963B2
(ja)
|
2002-08-24 |
2011-06-08 |
アストラゼネカ・アクチエボラーグ |
ケモカインレセプター活性のモジュレーターとしてのピリミジン誘導体
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
EP1847539B1
(en)
|
2002-12-24 |
2009-08-05 |
AstraZeneca AB |
Quinazoline derivatives
|
CA2516078C
(en)
|
2003-02-28 |
2014-04-29 |
Oxigene, Inc. |
Catechol compositions and use thereof
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
NZ547481A
(en)
|
2003-11-19 |
2009-12-24 |
Array Biopharma Inc |
Heterocyclic inhibitors of mek and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
EP1732920B1
(en)
|
2004-01-05 |
2011-03-09 |
AstraZeneca AB |
Thiophene derivatives as chk 1 inhibitors
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
DK1809624T3
(da)
|
2004-08-28 |
2014-01-20 |
Astrazeneca Ab |
Pyrimidinsulfonamidderivater som kemokinreceptor-modulatorer
|
SI1838733T1
(sl)
|
2004-12-21 |
2011-12-30 |
Medimmune Ltd |
Protitelesa usmerjena na angiopoietin-2 in njih uporaba
|
ATE530545T1
(de)
|
2005-02-04 |
2011-11-15 |
Astrazeneca Ab |
Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
|
NZ587190A
(en)
|
2005-05-18 |
2011-11-25 |
Array Biopharma Inc |
Heterocyclic inhibitors of MEK and methods of use thereof wherein teh inhibitor compounds have a dihydropyridazine core
|
BRPI0613563A2
(pt)
|
2005-07-21 |
2012-01-17 |
Astrazeneca Ab |
novos derivados de piperidina
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
WO2007034917A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規なアデニン化合物
|
JPWO2007034881A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
EP1939199A4
(en)
|
2005-09-22 |
2010-10-20 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
WO2007034817A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
WO2007039736A1
(en)
|
2005-10-06 |
2007-04-12 |
Astrazeneca Ab |
Novel compounds
|
TW200800963A
(en)
|
2005-10-28 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
SI2090575T1
(sl)
|
2005-11-15 |
2011-08-31 |
Array Biopharma Inc |
Postopki in intermediati za pripravo N4-fenil-kinazolin-4-aminskih derivatov
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
AU2006326649B2
(en)
|
2005-12-13 |
2011-03-24 |
Medimmune Limited |
Binding proteins specific for insulin-like growth factors and uses thereof
|
WO2007068894A2
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2125722A2
(en)
|
2006-05-26 |
2009-12-02 |
AstraZeneca AB |
Bi-aryl or aryl-heteroaryl substituted indoles
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
HRP20170627T1
(hr)
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- i pirimido-pirimidina kao inhibitori mtor
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US20100113510A1
(en)
|
2006-12-19 |
2010-05-06 |
Rhonan Ford |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
BRPI0817941A2
(pt)
|
2007-10-04 |
2015-05-05 |
Astrazeneca Ab |
Compostos de pirazol de [3,2-c] esteroidais, com atividade glucocorticóide
|
TWI453021B
(zh)
|
2007-10-11 |
2014-09-21 |
Astrazeneca Ab |
新穎蛋白質激酶b抑制劑
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
AU2008339576B2
(en)
|
2007-12-21 |
2014-05-22 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US8148373B2
(en)
|
2008-02-06 |
2012-04-03 |
Astrazeneca Ab |
Compounds
|
EP2254889B1
(en)
|
2008-02-28 |
2012-12-19 |
Merck Patent GmbH |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2297106B1
(en)
|
2008-05-27 |
2014-07-16 |
AstraZeneca AB |
Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
TWI461423B
(zh)
|
2008-07-02 |
2014-11-21 |
Astrazeneca Ab |
用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
KR20110057244A
(ko)
|
2008-09-19 |
2011-05-31 |
메디뮨 엘엘씨 |
Dll4에 대한 항체 및 이의 용도
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
BRPI0923504A2
(pt)
|
2008-12-11 |
2020-05-26 |
Axcentua Pharmaceuticals Ab |
Formas cristalinas de genisteína.
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
CA2745071C
(en)
|
2008-12-17 |
2018-08-28 |
Yufang Xiao |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
US8853391B2
(en)
|
2008-12-18 |
2014-10-07 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
CA2749926A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
KR20120099639A
(ko)
|
2009-10-02 |
2012-09-11 |
아스트라제네카 아베 |
호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
AU2010322478B2
(en)
|
2009-11-18 |
2013-11-14 |
Glaxosmithkline Intellectual Property (No. 3) Limited |
Benzoimidazole compounds and uses thereof
|
MX359551B
(es)
|
2009-11-24 |
2018-10-02 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
ES2438509T3
(es)
|
2009-12-14 |
2014-01-17 |
Merck Patent Gmbh |
Inhibidores de la esfingosina quinasa
|
AU2010341229A1
(en)
|
2009-12-17 |
2012-08-02 |
Merck Patent Gmbh |
Sphingosine kinase inhibitors
|
CN103980338B
(zh)
|
2010-01-15 |
2017-04-26 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
KR20120120307A
(ko)
|
2010-01-19 |
2012-11-01 |
아스트라제네카 아베 |
피라진 유도체
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
JP2013542916A
(ja)
|
2010-11-19 |
2013-11-28 |
大日本住友製薬株式会社 |
環状アミド化合物および疾患の処置におけるその使用
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
CN103370317B
(zh)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
WO2012085015A1
(en)
|
2010-12-20 |
2012-06-28 |
Medimmune Limited |
Anti-il-18 antibodies and their uses
|
CN103619865B
(zh)
|
2011-02-02 |
2016-10-12 |
苏州润新生物科技有限公司 |
某些化学个体、组合物及方法
|
DK2675793T3
(en)
|
2011-02-17 |
2018-11-12 |
Cancer Therapeutics Crc Pty Ltd |
FAK INHIBITORS
|
US9174946B2
(en)
|
2011-02-17 |
2015-11-03 |
Cancer Therapeutics Crc Pty Ltd |
Selective FAK inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
KR101946664B1
(ko)
|
2011-07-12 |
2019-02-11 |
아스트라제네카 아베 |
케모카인 수용체 조절제로서의 n-(6-((2r,3s)-3,4-디히드록시부탄-2-일옥시)-2-(4-플루오로벤질티오)피리미딘-4-일)-3-메틸아제티딘-1-술폰아미드
|
LT3009431T
(lt)
|
2011-07-27 |
2018-01-10 |
Astrazeneca Ab |
2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
CN107245056A
(zh)
|
2011-08-26 |
2017-10-13 |
润新生物公司 |
化学实体、组合物及方法
|
EP2753174A4
(en)
|
2011-09-01 |
2015-05-20 |
Xiangping Qian |
PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
CN115403531A
(zh)
|
2011-09-14 |
2022-11-29 |
润新生物公司 |
作为激酶抑制剂的化学实体、组合物及方法
|
US9249110B2
(en)
|
2011-09-21 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
US20140235573A1
(en)
|
2011-09-29 |
2014-08-21 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
EP2806874B1
(en)
|
2012-01-25 |
2017-11-15 |
Neupharma, Inc. |
Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
|
US9409914B2
(en)
|
2012-01-28 |
2016-08-09 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
PL2812337T3
(pl)
|
2012-02-09 |
2017-01-31 |
Merck Patent Gmbh |
Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikk
|
DK2812323T3
(en)
|
2012-02-09 |
2016-05-09 |
Merck Patent Gmbh |
TETRAHYDRO-quinazolinone derivatives BY TANKERS AND PARPINHIBITORER
|
ES2674451T3
(es)
|
2012-02-21 |
2018-06-29 |
Merck Patent Gmbh |
2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
|
EP2817306B1
(en)
|
2012-02-21 |
2015-09-16 |
Merck Patent GmbH |
Cyclic diaminopyrimidine derivatives as syk inhibitors
|
WO2013124025A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Furopyridine derivatives
|
CA2866450C
(en)
|
2012-03-07 |
2020-02-18 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
HRP20160908T1
(hr)
|
2012-03-28 |
2016-09-23 |
Merck Patent Gmbh |
Biciklički derivati pirazinona
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
MX2014011818A
(es)
|
2012-04-05 |
2014-12-10 |
Hoffmann La Roche |
Anticuerpos biespecificos contra inductor debil de la apoptosis relacionado con el tnf (tweak) humana e il17 humana y usos de los mismos.
|
US9340570B2
(en)
|
2012-04-29 |
2016-05-17 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
MX357502B
(es)
|
2012-05-04 |
2018-07-12 |
Merck Patent Gmbh |
Derivados de pirrolotriazinona.
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
CN104507957B
(zh)
|
2012-07-24 |
2018-12-25 |
默克专利股份有限公司 |
用于治疗关节病的羟基他汀衍生物
|
AU2013301865B2
(en)
|
2012-08-07 |
2017-08-17 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
WO2014023390A2
(en)
|
2012-08-08 |
2014-02-13 |
Merck Patent Gmbh |
(aza-)isoquinolinone derivatives
|
WO2014026243A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CN104662006B
(zh)
|
2012-09-26 |
2017-10-24 |
默克专利股份公司 |
作为parp抑制剂的喹唑酮衍生物
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
EP3354752B1
(en)
|
2012-11-05 |
2020-03-11 |
GMDx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
EP2916838B1
(en)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
KR20150085045A
(ko)
|
2012-11-16 |
2015-07-22 |
메르크 파텐트 게엠베하 |
3-아미노시클로펜탄 카르복사미드 유도체
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
KR102120513B1
(ko)
|
2013-01-31 |
2020-06-08 |
네오메드 인스티튜트 |
이미다조피리딘 화합물 및 이의 용도
|
EP2958901B1
(de)
|
2013-02-25 |
2016-11-02 |
Merck Patent GmbH |
2-amino-3,4-dihydro-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
|
ES2614872T3
(es)
|
2013-03-05 |
2017-06-02 |
Merck Patent Gmbh |
Derivados de 9-(aril o heteroaril)-2-(pirazolilo, pirrolidinilo o ciclopentilo) aminopurina como agentes anticancer
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
CA2905509A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
US9937137B2
(en)
|
2013-03-15 |
2018-04-10 |
Neurocentria, Inc. |
Magnesium compositions and uses thereof for cancers
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
WO2014195507A1
(en)
|
2013-06-07 |
2014-12-11 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
EP3013424B1
(en)
|
2013-06-25 |
2024-09-25 |
EpiAxis Therapeutics Pty Ltd |
Lsd inhibitors for modulating cancer stem cells
|
PH12019500143B1
(en)
|
2013-08-23 |
2023-03-24 |
Neupharma Inc |
Certain chemical entities, compositions, and methods
|
EP3046560B1
(en)
|
2013-09-18 |
2021-01-06 |
EpiAxis Therapeutics Pty Ltd |
Stem cell modulation ii
|
WO2015048852A1
(en)
|
2013-10-01 |
2015-04-09 |
The University Of Queensland |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
CA2958704A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
US20190072557A1
(en)
|
2014-11-17 |
2019-03-07 |
The University Of Queensland |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
WO2016133935A1
(en)
|
2015-02-17 |
2016-08-25 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
JP6842458B2
(ja)
|
2015-08-04 |
2021-03-17 |
オーセントラ セラピュティクス ピーティーワイ エルティーディーAucentra Therapeutics Pty Ltd |
治療化合物としてのn−(ピリジン−2−イル)−4−(チアゾール−5−イル)ピリミジン−2−アミン誘導体
|
CN116574809A
(zh)
|
2015-08-26 |
2023-08-11 |
Gmdx私人有限公司 |
检测癌症复发的方法
|
WO2017106926A1
(en)
|
2015-12-23 |
2017-06-29 |
Queensland University Of Technology |
Nucleic acid oligomers and uses therefor
|
US10487115B2
(en)
|
2016-02-01 |
2019-11-26 |
University Of Canberra |
Proteinaceous compounds and uses therefor
|
TWI827530B
(zh)
|
2016-02-15 |
2024-01-01 |
瑞典商阿斯特捷利康公司 |
包括對西地尼布進行固定的間歇給藥之方法
|
DK3442535T3
(da)
|
2016-04-15 |
2022-09-05 |
Cancer Research Tech Ltd |
Heterocykliske stoffer som as ret-kinase-hæmmere
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
PL3490565T3
(pl)
|
2016-07-29 |
2022-09-26 |
Rapt Therapeutics, Inc. |
Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
|
AU2017312561B2
(en)
|
2016-08-15 |
2022-06-30 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
AU2017332839B2
(en)
|
2016-09-22 |
2021-11-11 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
JP7071392B2
(ja)
|
2016-12-05 |
2022-05-18 |
アプロス セラピューティクス, インコーポレイテッド |
酸性基を含有するピリミジン化合物
|
AU2018214431B2
(en)
|
2017-02-01 |
2021-07-29 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
US10703723B2
(en)
|
2017-03-09 |
2020-07-07 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
IL302300A
(en)
|
2017-05-26 |
2023-06-01 |
The Institute Of Cancer Res Royal Cancer Hospital |
Benzimidazolone derived inhibitors of bcl6
|
ES2975661T3
(es)
|
2017-05-26 |
2024-07-11 |
Cancer Research Tech Ltd |
Inhibidores de BCL6 derivados de la 2-quinolona
|
WO2018220101A1
(en)
|
2017-05-31 |
2018-12-06 |
Truly Translational Sweden Ab |
A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
WO2019007447A1
(en)
|
2017-07-05 |
2019-01-10 |
E.P.O.S Iasis Research And Development Limited |
MULTIFUNCTIONAL CONJUGATES
|
HUE061308T2
(hu)
|
2017-08-01 |
2023-06-28 |
Merck Patent Gmbh |
Tiazolopiridin-származékok mint adenozin receptor antagonisták
|
EP3668882A1
(en)
|
2017-08-18 |
2020-06-24 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
AU2018320673B2
(en)
|
2017-08-21 |
2023-03-30 |
Merck Patent Gmbh |
Benzimidazole derivatives as adenosine receptor antagonists
|
WO2019038214A1
(en)
|
2017-08-21 |
2019-02-28 |
Merck Patent Gmbh |
QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
JP2021502345A
(ja)
|
2017-11-06 |
2021-01-28 |
ラプト・セラピューティクス・インコーポレイテッド |
抗がん剤
|
DK3488868T3
(da)
|
2017-11-23 |
2023-11-27 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Farmaceutisk sammensætning til oral indgivelse, som indeholder sulfasalazin og/eller et organisk sulfasalazinsalt, fremstillingsfremgangsmåde samt anvendelse
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
EP3740484B1
(en)
|
2018-01-15 |
2024-09-11 |
Aucentra Therapeutics Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
RU2020128176A
(ru)
|
2018-01-26 |
2022-03-02 |
Рапт Терапьютикс, Инк. |
Модуляторы рецепторов хемокинов и их применение
|
JP7550646B2
(ja)
|
2018-02-08 |
2024-09-13 |
ニューファーマ,インク. |
特定の化学物質、組成物、および方法
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
KR20250105504A
(ko)
|
2018-04-13 |
2025-07-08 |
캔써 리서치 테크놀로지 리미티드 |
Bcl6 저해제
|
AU2019260793B2
(en)
|
2018-04-27 |
2023-05-18 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
WO2019236496A1
(en)
|
2018-06-04 |
2019-12-12 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
EP4360713B1
(en)
|
2018-09-18 |
2024-10-30 |
F. Hoffmann-La Roche AG |
Quinazoline derivatives as antitumor agents
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
EP3870294A1
(en)
|
2018-10-25 |
2021-09-01 |
Merck Patent GmbH |
5-azaindazole derivatives as adenosine receptor antagonists
|
EP3870582B1
(en)
|
2018-10-25 |
2023-07-19 |
Merck Patent GmbH |
5-azaindazole derivatives as adenosine receptor antagonists
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
WO2020132844A1
(zh)
|
2018-12-25 |
2020-07-02 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
AU2020232026A1
(en)
|
2019-03-07 |
2021-09-02 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
US12358915B2
(en)
|
2019-04-05 |
2025-07-15 |
STORM Therapeutics Ltd. |
METTL3 inhibitory compounds
|
TWI846855B
(zh)
|
2019-04-08 |
2024-07-01 |
德商馬克專利公司 |
作為shp2拮抗劑的嘧啶酮衍生物
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
KR20220054840A
(ko)
|
2019-08-31 |
2022-05-03 |
이턴 바이오파마 (상하이) 코., 엘티디. |
Fgfr 억제제용 피라졸류 유도체 및 이의 제조방법
|
KR20220066922A
(ko)
|
2019-09-20 |
2022-05-24 |
아이디어야 바이오사이언시스 인코포레이티드 |
Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
CN115151540A
(zh)
|
2019-12-02 |
2022-10-04 |
风暴治疗有限公司 |
作为mettl3抑制剂的多杂环化合物
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
US20230391770A1
(en)
|
2020-10-06 |
2023-12-07 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
US20250281633A1
(en)
|
2021-05-03 |
2025-09-11 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
US20240246948A1
(en)
|
2021-05-17 |
2024-07-25 |
Hk Inno.N Corporation |
Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
|
WO2022248380A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
EP4413000A1
(en)
|
2021-10-04 |
2024-08-14 |
FoRx Therapeutics AG |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
IL314200A
(en)
|
2022-01-10 |
2024-09-01 |
Merck Patent Gmbh |
Heterocycles are being converted as HSET inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
KR20240171145A
(ko)
|
2022-04-06 |
2024-12-06 |
랩트 테라퓨틱스, 인크. |
케모카인 수용체 조절제 및 이의 용도
|
US20250304576A1
(en)
|
2022-05-11 |
2025-10-02 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
EP4565592A1
(en)
|
2022-08-01 |
2025-06-11 |
Neupharma, Inc. |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
EP4612148A1
(en)
|
2022-11-02 |
2025-09-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
EP4612149A1
(en)
|
2022-11-02 |
2025-09-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
EP4615838A1
(en)
|
2022-11-07 |
2025-09-17 |
Merck Patent GmbH |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
GB202300881D0
(en)
|
2023-01-20 |
2023-03-08 |
Neophore Ltd |
Inhibitor compounds
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
US12145945B2
(en)
|
2023-03-10 |
2024-11-19 |
Breakpoint Therapeutics Gmbh |
Compounds, compositions, and therapeutic uses thereof
|
WO2024209035A1
(en)
|
2023-04-05 |
2024-10-10 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
GB202306601D0
(en)
|
2023-05-04 |
2023-06-21 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB202307924D0
(en)
|
2023-05-26 |
2023-07-12 |
Neophore Ltd |
Inhibitor compounds
|
GB2631507A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
GB2631509A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
WO2025046148A1
(en)
|
2023-09-01 |
2025-03-06 |
Forx Therapeutics Ag |
Novel parg inhibitors
|
WO2025056923A1
(en)
|
2023-09-15 |
2025-03-20 |
Cambridge Enterprise Limited |
Combination therapy
|
WO2025073792A1
(en)
|
2023-10-02 |
2025-04-10 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
WO2025073870A1
(en)
|
2023-10-03 |
2025-04-10 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
GB202315149D0
(en)
|
2023-10-03 |
2023-11-15 |
Celleron Therapeutics Ltd |
Combination therapy
|
GB202316595D0
(en)
|
2023-10-30 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
GB202316683D0
(en)
|
2023-10-31 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
WO2025093755A1
(en)
|
2023-11-01 |
2025-05-08 |
Forx Therapeutics Ag |
Novel parc inhibitors
|
GB202317368D0
(en)
|
2023-11-13 |
2023-12-27 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
WO2025104443A1
(en)
|
2023-11-14 |
2025-05-22 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
WO2025114480A1
(en)
|
2023-11-28 |
2025-06-05 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
WO2025136811A1
(en)
|
2023-12-18 |
2025-06-26 |
Ideaya Biosciences, Inc. |
Chemical compounds and uses thereof
|
GB202319863D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Movel compounds, compositions and therapeutics uses thereof
|
GB202319864D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
WO2025133396A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Novel bicyclo heteroaryl parg inhibitors
|
WO2025133395A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Bicyclic (hetero)arylene wrn inhibitory compounds
|
WO2025191176A1
(en)
|
2024-03-14 |
2025-09-18 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|